Management of Diabetes With Metformin In Patients With Chronic Heart Failure

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will assess the use of the medication metformin to improve quality of life, exercise capacity, and improved outcomes with patients that have both heart failure and diabetes.

If you participate in this study, you will receive the drug metformin for approximately 3 months. During the study you will undergo comprehensive testing which includes blood draws, an echocardiogram, and an magnetic resonance imaging (MRI)(if you do not have a pacemaker or defibrillator). You will also fill out a questionnaire and keep a blood glucose log.

You must be 18 years old to participate. The study drugs, study follow-up visits, and laboratory tests will be provided free of charge. Participants will be reimbursed up to $200 for their time and travel expenses.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Systolic HF of any etiology (left ventricular ejection fraction ≤ 40%)

• Previously-diagnosed, inadequately controlled DM (HbA1c≥7.5%)

• On any combination of anti-diabetic medications excluding metformin

Exclusion Criteria:

• Current metformin therapy

• Previous intolerance to metformin therapy

• Renal dysfunction (creatinine clearance < 60 ml/minute)

• History of lactic acidosis.